This ADC product is comprised of an anti-TPBG monoclonal antibody (clone A1) conjugated via a SMCC linker to DMA. The DMA is targeted to TPBG-positive cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis.
This gene encodes a leucine-rich transmembrane glycoprotein that may be involved in cell adhesion. The encoded protein is an oncofetal antigen that is specific to trophoblast cells. In adults this protein is highly expressed in many tumor cells and is associated with poor clinical outcome in numerous cancers. Alternate splicing in the 5 UTR results in multiple transcript variants that encode the same protein.
Disulfide Linkers, are extensively exploited as a chemically labile linkage. Since the release of disulfide-linked drugs requires a cytoplasmic thiol cofactor, such as glutathione (GSH). Disulfides maintain stable at physiological pH and only when ADCs are internalized inside cells, the cytosol provides reducing environment including intracellular enzyme protein disulfide isomerase, or similar enzymes, drugs can be released.